Adial Pharmaceuticals, Inc. (ADIL)
Automate Your Wheel Strategy on ADIL
With Tiblio's Option Bot, you can configure your own wheel strategy including ADIL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADIL
- Rev/Share 0.0
- Book/Share 5.0799
- PB 0.6142
- Debt/Equity 0.0
- CurrentRatio 4.3419
- ROIC -1.7435
- MktCap 2994089.0
- FreeCF/Share -7.4667
- PFCF -0.4522
- PE -0.3436
- Debt/Assets 0.0
- DivYield 0
- ROE -1.9771
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Published: February 04, 2026 by: GlobeNewsWire
Sentiment: Neutral
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today applauded the passage by Congress and signing into law by President Donald J. Trump of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2026.
Read More
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Published: October 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
GLEN ALLEN, Va., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial, was invited to appear as a featured guest on the Big Biz Show, an Emmy Award-winning nationally syndicated radio and TV program.
Read More
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
Published: May 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
GLEN ALLEN, Va., May 02, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced its entry into a warrant inducement agreement with an existing healthcare-focused institutional investor of the Company for the immediate exercise of existing Series B Warrants (the "Series B Warrants") to purchase up to 1,418,440 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), and Series C Warrants (the "Series C Warrants", and together with the Series B …
Read More
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use
Read More
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval
Read More
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders
Read More
About Adial Pharmaceuticals, Inc. (ADIL)
- IPO Date 2018-07-27
- Website https://www.adialpharma.com
- Industry Biotechnology
- CEO Cary John Claiborne
- Employees 5